Adherex Technologies (FENC) Expected to Announce Quarterly Earnings on Tuesday

Adherex Technologies (NASDAQ:FENC) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $13.7750 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings data on Saturday, March 28th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.21). Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%. The business had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.75 million. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Adherex Technologies Stock Performance

Shares of FENC traded up $0.13 during trading hours on Tuesday, hitting $6.78. The stock had a trading volume of 29,478 shares, compared to its average volume of 152,289. The firm has a 50-day moving average price of $7.11 and a 200 day moving average price of $7.65. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $9.92. The firm has a market capitalization of $234.19 million, a price-to-earnings ratio of -19.98 and a beta of 0.91.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Adherex Technologies in a research note on Friday, January 9th. They issued an “overweight” rating and a $18.00 target price for the company. B. Riley Financial assumed coverage on shares of Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price for the company. Wall Street Zen cut shares of Adherex Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Adherex Technologies in a research note on Thursday, April 16th. Finally, Zacks Research cut shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Insiders Place Their Bets

In other Adherex Technologies news, Director Rosty Raykov sold 10,946 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $6.31, for a total transaction of $69,069.26. Following the completion of the transaction, the director directly owned 113,856 shares in the company, valued at approximately $718,431.36. This represents a 8.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new position in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.